Compare ALX & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALX | NEO |
|---|---|---|
| Founded | 1928 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2008 |
| Metric | ALX | NEO |
|---|---|---|
| Price | $230.57 | $7.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 41.7K | ★ 1.3M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.50 | N/A |
| Revenue | ★ $213,183,000.00 | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $41.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $189.05 | $4.72 |
| 52 Week High | $260.84 | $13.74 |
| Indicator | ALX | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 40.62 |
| Support Level | $229.26 | $7.59 |
| Resistance Level | $235.65 | $8.89 |
| Average True Range (ATR) | 6.89 | 0.40 |
| MACD | -1.52 | 0.09 |
| Stochastic Oscillator | 22.11 | 61.38 |
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.